CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2012-04-26): Don't mix boceprevir with certain HIV drugs: FDA

Regulatory

Don't mix boceprevir with certain HIV drugs: FDA

Last Updated: 2012-04-26 15:50:27 -0400 (Reuters Health)

WASHINGTON (Reuters) - U.S. drug regulators are changing the label on the recently approved protease inhibitor boceprevir (Victrelis, Merck & Co) for treatment of hepatitis C virus (HCV) to state that it should not be taken with some widely used drugs for HIV infection.

Co-administration of boceprevir, along with certain ritonavir-boosted HIV protease inhibitors, "is not recommended at this time because of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV or HIV virus in the blood (viral load) to increase," the U.S. Food and Drug Administration (FDA) said Thursday.

Ritonavir-boosted HIV protease inhibitors include ritonavir-boosted Reyataz (atazanavir), ritonavir-boosted Prezista (darunavir), and Kaletra (lopinavir/ritonavir).

The FDA advises, "Healthcare professionals who started patients infected with both chronic HCV and HIV on Victrelis while the patient was taking antiretroviral therapy containing one of these ritonavir-boosted protease inhibitors should closely monitor patients for treatment response (no HCV virus detected in the blood) and for potential HCV or HIV virologic rebound."

The FDA and Merck first warned about the issue back in February based on the results of a drug-drug interaction study, which showed that taking boceprevir with any one of the three ritonavir-boosted HIV protease inhibitors could reduce the desired blood levels of both medicines.

The FDA said it is changing the label for boceprevir also based on preliminary results of a small clinical trial presented last month at the 19th Conference on Retroviruses and Opportunistic Infections.

Merck has said it still plans a larger drug-interaction trial of boceprevir with other HIV drugs.

The FDA said it would communicate any new information about taking boceprevir together with the HIV drugs when it becomes available.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.